NRX:CA:TSV-NurExone Biologic Inc. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.49

Change

-0.01 (-2.00)%

Market Cap

USD 0.04B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

-0.05 (-2.50%)

USD 0.14B
ARCH:CA Arch Biopartners Inc

-0.02 (-1.18%)

USD 0.10B
MIR:CA MedMira Inc

+0.01 (+5.88%)

USD 0.06B
COV:CA Covalon Technologies Ltd.

+0.09 (+4.31%)

USD 0.05B
TTI:CA Thiogenesis Therapeutics Corp.

+0.01 (+1.45%)

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
CZO:CA Ceapro

-0.03 (-11.76%)

USD 0.02B
KNE:CA Kane Biotech Inc

-0.01 (-3.85%)

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

+0.01 (+10.00%)

USD 0.02B

ETFs Containing NRX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 66.10% 90% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.10% 90% A- 86% B+
Trailing 12 Months  
Capital Gain 88.46% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.46% 100% F 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.37% 64% D 57% F
Dividend Return 5.37% 64% D 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.19% 55% F 50% F
Risk Adjusted Return 10.92% 64% D 59% D-
Market Capitalization 0.04B 86% B+ 82% B

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.